EBS241220C6000
- 2.25
- +0.13+6.13%
Emergent BioSolutions Newsroom
Sector Update: Health Care
Emergent BioSolutions Wins $50 Million Contract Option for Cyfendus; Shares Rise
Express News | Emergent BioSolutions Inc - Cyfendus Vaccine Deliveries Expected to Complete by April 2025
Express News | Emergent BioSolutions Receives $50 Million Contract Option From Barda to Procure Doses of Cyfendus® (Anthrax Vaccine Adsorbed, Adjuvanted)
Investors Don't See Light At End Of Emergent BioSolutions Inc.'s (NYSE:EBS) Tunnel And Push Stock Down 26%
Emergent BioSolutions Inc.'s (NYSE:EBS) Institutional Investors Lost 11% Last Week but Have Benefitted From Longer-term Gains
WHO Extends Mpox Emergency; Canada Reports First Clade I Case
Express News | World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern
First Mpox Case Linked to African Outbreak Reported in U.S.
Have Emergent BioSolutions Insiders Been Selling Stock?
US Manufacturing Index Rises To 43, Highest Since 2020
Vaccines Makers Close Lower on Reports RFK Jr May Head HHS
Emergent Biosolutions Insider Sold Shares Worth $272,750, According to a Recent SEC Filing
Emergent BioSolutions Files to Sell 3.61M Shares of Common Stock for Holders
Emergent BioSolutions (NYSE:EBS) Has Debt But No Earnings; Should You Worry?
Express News | India's Business Standard Reported New Study Claims Mpox Clade La Has Evolved To Spread From Human To Human, Citing October 24 Uploaded Paper On Virologica
Emergent Software Welcomes Industry Leader Marc Kermisch as Chief Technology Officer
Emergent BioSolutions Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
Emergent Biosolutions Shares Surge 28% After Swinging to 3Q Profit